Shots:

• Health Canada has authorized the use of Paxlovid (BID, for 5 days) for the treatment of mild-to-moderate COVID-19 in adults aged ≥18yrs.
• The authorization is based on the P-II/III (EPIC-HR) trial to evaluate Paxlovid in non-hospitalized adults aged ≥18 with confirmed COVID-19 who are at high risk of progressing to severe illness including hospitalization or death. Additionally, the trial is ongoing in adults at low risk of hospitalization & who have been exposed to the virus through household contacts
• Paxlovid is a SARS-CoV-2 main protease (Mpro) inhibitor. In Dec 2021, Pfizer collaborated with the Government of Canada to supply 1M treatment courses of Paxlovid in 2022

Ref: Newswire.Ca | Image: The Wall Street Journal